文献速递脑血管病外科神经重症

多种治疗药物对动脉瘤性蛛网膜下腔出血后血管痉挛和功能结局的影响:一项网状Meta分析

Effects of Various Therapeutic Agents on Vasospasm and Functional Outcome After Aneurysmal Subarachnoid Hemorrhage-Results of a Network Meta-Analysis.
PubMed 文献 · World Neurosurg · 2021-07-30

该网状Meta分析纳入57项随机对照试验,比较多种药物对动脉瘤性蛛网膜下腔出血后功能结局及血管痉挛的影响。尼卡地平缓释植入物在改善良好结局、降低死亡率和预防血管造影血管痉挛方面均最优,西洛他唑次之。法舒地尔在降低血管流速增高方面最佳,依诺肝素在预防迟发性缺血性神经功能缺损方面最佳。

要点

  • 尼卡地平缓释植入物与最佳良好结局、最低死亡率和最少血管造影血管痉挛相关。
  • 西洛他唑为改善良好结局和降低死亡率的第二优治疗。
  • 法舒地尔最佳降低血管流速增高,依诺肝素最佳预防迟发性缺血性神经功能缺损。

核心结论

  • 尼卡地平缓释植入物和西洛他唑与动脉瘤性蛛网膜下腔出血患者改善良好结局和死亡率的最佳机会相关。
  • 需要来自世界其他地区的更大规模多中心研究来确认这些发现。

研究设计与样本

  • 网状Meta分析,全面检索多个数据库以获取描述各种治疗对动脉瘤性蛛网膜下腔出血后功能结局及其他参数影响的随机对照试验。

主要发现

  • 尼卡地平缓释植入物在良好结局方面最优(OR 8.55,95% CrI 1.63-56.71),降低死亡率(OR 0.08,95% CrI 0-0.82),预防血管造影血管痉挛(OR 0.018,95% CrI 0.00057-0.16)。
  • 西洛他唑在改善良好结局方面为第二优(OR 3.58,95% CrI 1.97-6.57),降低死亡率(OR 0.41,95% CrI 0.12-1.15)。
  • 法舒地尔在降低血管流速增高方面最佳(OR 0.16,95% CrI 0.03-0.78)。
  • 依诺肝素在预防迟发性缺血性神经功能缺损方面最佳(OR 0.25,95% CrI 0.057-1.0)。

局限性

  • 需要来自世界其他地区的更大规模多中心研究来确认这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vasospasm and delayed ischemic neurologic deficits are the leading causes of morbidity and mortality after aneurysmal subarachnoid hemorrhage (aSAH). Several therapeutic agents have been assessed in randomized controlled trials for their efficacy in reducing the incidence of vasospasm and improving functional outcome. The aim of this network meta-analysis is to compare all these therapeutic agents for their effect on functional outcome and other parameters after aSAH. METHODS: A comprehensive search of different databases was performed to retrieve randomized controlled trials describing the effect of various therapeutic approaches on functional outcome and other parameters after aSAH. RESULTS: Ninety-two articles were selected for full text review and 57 articles were selected for the final analysis. Nicardipine prolonged-release implants were found to be the best treatment in terms of favorable outcome (odds ratio [OR], 8.55; 95% credible interval [CrI], 1.63-56.71), decreasing mortality (OR, 0.08; 95% CrI, 0-0.82), and preventing angiographic vasospasm (OR, 0.018; 95% CrI, 0.00057-0.16). Cilostazol was found to be the second-best treatment in improving favorable outcomes (OR, 3.58; 95% CrI, 1.97-6.57) and decreasing mortality (OR, 0.41; 95% CrI, 0.12-1.15). Fasudil (OR, 0.16; 95% CrI, 0.03-0.78) was found to be the best treatment in decreasing increased vessel velocity and enoxaparin (OR, 0.25; 95% CrI, 0.057-1.0) in preventing delayed ischemic neurologic deficits. CONCLUSIONS: Our analysis showed that nicardipine prolonged-release implants and cilostazol were associated with the best chance of improving favorable outcome and mortality in patients with aSAH. However, larger multicentric studies from other parts of the world are required to confirm these findings.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Mishra S, Garg K, Gaonkar VB, et al. Effects of Various Therapeutic Agents on Vasospasm and Functional Outcome After Aneurysmal Subarachnoid Hemorrhage-Results of a Network Meta-Analysis. World Neurosurg. 2021. PMID: 34339892. doi:10.1016/j.wneu.2021.07.104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。